Alexion Pharma (ALXN) Tops Q3 EPS by 6c; Guides Relativity In-Line

Alexion Pharma (NASDAQ: ALXN) reported Q3 EPS of $1.23, $0.06 better than the analyst estimate of $1.17. Revenue for the quarter came in at $799 million versus the consensus estimate of $786.86 million.

GUIDANCE:

Alexion Pharma sees FY2016 EPS at upper end of $4.50-$4.65, versus the consensus of $4.67. Alexion Pharma sees FY2016 revenue of $3.05-3.10 billion, versus the consensus of $3.08 billion.

“In Q3 2016, we delivered strong financial performance and served an increasing number of patients with PNH, aHUS, HPP and LAL-D, while also achieving significant R&D milestones,” said David Hallal, Chief Executive Officer of Alexion. “As we continue to grow our complement and metabolic businesses, we are working with urgency to file our regulatory submissions for eculizumab for the treatment of patients with refractory gMG in both the U.S. and Europe, and to enroll patients with PNH and aHUS into the global ALXN1210 registration trials.”

For earnings history and earnings-related data on Alexion Pharma (ALXN) click here.

You May Also Be Interested In

• SpaceX (SPCX) PT Raised to $230 at Goldman Sachs ahead of earnings release
• Allegion acquires specialty door maker Overly Door Company
• FactSet (FDS) Tops Q4 EPS by 17c, Beats on Revenue; Offers FY Guidance